
### **Bone Health and IBD**

Ashwin N Ananthakrishnan, MD, MPH
Associate Professor of Medicine
Massachusetts General Hospital
Harvard Medical School



MIIBDXXIII: The Master Class
Toronto, Canada
November 2022



## Bone Health in IBD Objectives


- Prevalence of osteoporosis and fracture in IBD
- Assessment of Bone Health
- Management of osteoporosis in IBD
- Role of vitamin D in the management of IBD

## Bone Health in IBD Prevalence of Osteoporosis

- Prevalence of osteoporosis in IBD: 3-42%
  - Depends on population (age, disease features)
  - Mode of assessment (DXA vs. clinical assessment)
- Systematic review: 12 studies, 3,661 patients with IBD
  - All IBD: 2-16%
    - -Crohn's disease: 7-15%
    - -Ulcerative colitis: 2-9%
  - General population: 3-10%

## Bone Health in IBD Prevalence of Osteoporosis

- Population-based cohort in Denmark (2003-04) of 513 patients with IBD (213 CD / 300 UC)
- 62% received a cumulative dose of prednisone >500mg/day.



Osteoporosis may also be common in patients with newly diagnosed IBD with 0-5%

## Bone Health in IBD Systematic review of osteoporosis

- Systematic review of 16 studies examining bone mineral density in patients with IBD
  - Patients with IBD have lower BMD at the femoral neck as well as lumbar spine

	Change vs. controls	P-value
Femoral Neck		
BMD	-0.04g/cm2	0.001
Z-score	-0.45	< 0.00001
Total Femur		
BMD	-0.08g/cm2	< 0.00001
Z-score	-1.01	0.07
Lumbar Spine		
BMD	-0.06g/cm2	0.001
Z-score	-0.52	< 0.00001

# Bone Health in IBD Osteoporosis



### Bone Health in IBD Fracture Risk in IBD


- Data from Korean National Health Insurance Claims (2007-16)
- Fracture incidence over 7 years compared in 18,228 patients with IBD compared to 186,871 controls.

	All patients	Steroid users
General Population	1.0	1.0
IBD	1.24	1.37
UC	1.16	1.33
CD	1.56 Vertebral: 1.88 Hip: 0.95	1.50

## Bone Health in IBD Risk Factors for osteoporosis


- Female gender
- Older age
- Family history of osteoporosis
- Low body mass index
- Shorter Height
- Ethnicity (Caucasian and Asian)
- Smoking
- Excess alcohol intake

## Bone Health in IBD Risk factors for osteoporosis in IBD



## Bone Health in IBD Steroid-induced osteoporosis

Steroid-induced osteoporosis occurs in 2 phases



## Bone Health in IBD Steroid-induced osteoporosis

- Steroids also decrease intestinal calcium absorption resulting in increase PTH and increased resorption
- Fractures may be noted in as many as 30-50% of steroid users
- Increase in fracture risk can be noted with as low as 2.5-7.5mg/day of prednisone use or within 30 days of use
- Incidence of fracture is higher with higher dose, longer duration, and advanced age.


### Bone Health in IBD Assessment of Bone Health: Who?

#### Recommendations for screening:

- Women > 65 years
- Men > 70 years
- Adults with fracture > 50 years
- Any adult with fracture not caused by severe trauma
- Younger women with fracture risk similar to a 65 year old
- Adults with a condition or medication use that increases fracture risk
  - Prednisone-equivalent > 7.5mg/day for > 3 months

### Bone Health in IBD Assessment of Bone Health: Who?

The FRAX tool calculates the 10-yr probability of hip fracture and major osteoporosis-related fracture



#### High risk:

- ≥20% for major FF (or)
- ≥ 3% for hip FF

### Bone Health in IBD Assessment of Bone Health: How?

- Dual Energy x-ray absorptiometry
  - Most widely used
  - Measures bone mineral content (BMC) and bone area (BA)
  - BMD = BMC / BA (in g/cm2)



#### Sites of measurement:

- Lumbar Spine
- Proximal femur
- Femur neck

Diagnosis	T-score
Normal	> -1.0
Low Bone mass	Between -1.0 and -2.5
Osteoporosis	≤-2.5
Severe osteoporosis	≤-2.5 and fragility fracture

## Bone Health in IBD Secondary Osteoporosis

Chronic conditions that contribute to accelerated bone loss

#### **Endocrine or metabolic causes**

Acromegaly

Anorexia nervosa

Athletic amenorrhea

Diabetes mellitus (type 1)

Hemochromatosis

Hyperadrenocorticism

Hyperparathyroidism

Hyperprolactinemia

**Thyrotoxicosis** 

#### Collagen/genetic disorders

Ehlers-Danlos syndrome

Glycogen storage diseases

Homocystinuria

Hypophosphatasia

Marfan syndrome

Osteogenesis imperfecta

#### **Medications**

Cyclosporine (Sandimmune)

Excess thyroid hormone

Glucocorticoids

**GnRH** agonists

Methotrexate (Rheumatrex)

Phenobarbital

**Phenothiazines** 

Phenytoin (Dilantin)

Heparin, prolonged treatment

#### **Nutritional**

**Alcoholism** 

Calcium deficiency

Chronic liver disease

Gastric operations

Malabsorption syndromes

Vitamin D deficiency

## Bone Health in IBD Non-Pharm Treatment of ostoeporosis

- Maintain sufficient calcium and vitamin D intake
  - Target serum vitamin D: 30-50ng/mL
    - Daily supplementation of > 400-800 IU
  - Calcium intake 1000-1200mg daily
    - Preferably through diet
    - Calcium supplementation in non-institutionalized adults is not supported by evidence
- Reduce intake of caffeine ≤ 4 cups of coffee / day
- Smoking cessation
- Reduce alcohol consumption < 2 drinks / day</li>
- Fall Risk assessment
- Physical Therapy and Exercise


### Bone Health in IBD **Exercise and BMD**


- 117 patients with CD were randomized to low-impact exercise or control for 12 months
- Overall cohort: No difference in BMD in exercise group and controls.
- Fully compliant cohort: Exercise was associated with increase in BMD
  - Increases in BMD were significantly related to the number of exercise sessions completed (femoral neck; r = 0.28 p = 0.04).

	Compliers	Control	% difference	P-value
Femoral neck	+3.5%	+0.5%	+2.99%	0.19
Lumbar spine	+2.97	+0.7%	+2.2%	0.30
Trochanter	+7.7%	+3.1%	+4.7%	0.02

### Bone Health in IBD **Exercise and BMD**

- 47 patients with CD were assigned to exercise (combined impact and resistance training, 3 60min session/week) x 6 months) or usual care
  - BMD values were superior in the exercise group with statistical significance at lumbar spine






The exercise group also had superior values muscle function outcomes

- Grip strength (GS)
- Chair stand test

## Bone Health in IBD Pharmacologic Treatment



Bisphosphonates
Anti-resorptive
Reduce osteoclast number
and function

Denosumab
Anti-resorptive
Monoclonal antibody that inhibits RANKL
Reduces osteoclast number, turnover,
and function


Teriparatide
Form of PTH
Aids in bone formation
Should only be used for 2 years
Abaloparatide: PTH analogue

Romosozumab
Inhibits sclerostin and activates the Wnt pathway promoting bone formation

Shoback D. J Clin Endocrinol Metab, 105(3): 2020, 587-594

### Bone Health in IBD Calcium and vitamin D

- \_ 154 patients with CD with decreased BMD were randomized to etidronate (400 mg orally) (or not) for 14 days;
- All received daily calcium 500mg and vitamin D 400 IU x 76 days.
- This cycle was repeated x 8 over 2 years



The increase in bone mineral density was similar in each treatment group.

### Bone Health in IBD Calcium and vitamin D

- 205 CD patients:
  - In osteopenic patients: Supplemental vitamin D (800 IU) and Calcium (500-1000 mg) were prescribed.
- \_ Among those with a second BMD in 4 years: Increase in mean BMD
  - L spine: +0.76% (95%CI: -2.63%; +3.87%)
  - Hip: +0.43% (95%CI: -2.65%; +1.11%)

## Bone Health in IBD Treatment of Osteoporosis in IBD

- Meta-analysis of bisphosphonates in IBD
  - 13 RCTs (923 patients (482 bisphosphonates, 441 control))
  - Treatment improved bone density at hip and T spine and reduced fracture risk
  - No increase in adverse effects


	Bisphosphonates		Control		Odds Ratio		Odds Ratio		Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixe	d. 95% CI	
Abitbol V 2007	0	33	1	34	7.4%	0.33 [0.01, 8.48]	-			
Haderslev KV 2000	1	17	2	15	10.1%	0.41 [0.03, 5.00]		•	_	
Henderson S 2006	1	23	1	25	4.6%	1.09 [0.06, 18.51]				
Kitazaki S 2009	0	16	0	18		Not estimable				
Klaus J 2011	0	54	1	32	9.4%	0.19 [0.01, 4.87]	_			
Palomba S 2005	5	40	14	41	61.2%	0.28 [0.09, 0.86]				
Van Bodegraven AA 2014	0	64	1	67	7.4%	0.34 [0.01, 8.59]	-	-	1	
Total (95% CI)		247		232	100.0%	0.33 [0.14, 0.77]		•		
Total events	7		20							
Heterogeneity: Chi <sup>2</sup> = 0.92, d	f = 5 (P = 0.97)	); I2 = 0%					0.000	04 4	40	F00
Test for overall effect: Z = 2.5	56 (P = 0.01)	7 F1540					0.002	0.1 1 osphonates	10 Favours con	500

### Bone Health in IBD Steroid-induced osteoporosis prevention

- Lowest dose, shortest duration, steroid-sparing regimens when able
- Topical therapy > enteral or parenteral glucocorticoids
- Weight bearing exercises to prevent both loss and muscle atrophy
- Avoid smoking and excess alcohol
- Fall prevention measures
- \_ Calcium (1000-1200mg/day) and vitamin D (600-800IU/day)
  - Meta-analysis of 5 trials: Improvement in BMD, no difference in fracture risk.
- Consider pharmacologic therapy if high fracture risk in postmenopausal women and men > 40 years


### Bone Health in IBD Vitamin D and IBD

- The Institute of Medicine defines vitamin D deficiency as 25-OH-D less than 20 ng/mL (50 nmol/L)\* (> 30ng/ml or 75 nmol / L is considered adequate)
  - \*Based on skeletal effects of vitamin D




### Bone Health in IBD Vitamin D and IBD: Observational data

 In observation studies, vitamin D deficiency is associated with more severe disease in IBD



### Bone Health in IBD Vitamin D and IBD: Interventions

Initial studies promising showed reduced rates of relapse in patients treated with vitamin D



- More recent pooled analysis of 17 trials with 1127 patients with IBD
  - Oral vitamin D supplementation
    - Increased serum vitamin D levels (12.15 ng mL<sup>-1</sup>;)
    - Reduced C-reactive protein levels (SMD -0.33)
    - Did not decrease ESR or disease activity index
    - Did not decrease rates of relapse (RR 0.59; 95% CI 0.19, 1.86)

### Bone Health in IBD Conclusions

- Suboptimal bone health can have profound consequenecs on patients with IBD, particularly the IBD
- Treating clinicians should routinely incorporate assessment of bone health in the management of patients with IBD
- Improving bone health importantly allows optimization of functional capacity

